These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 22903934

  • 1. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A.
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [Abstract] [Full Text] [Related]

  • 2. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
    Müller V, Perrakis A, Meyer J, Förtsch T, Korn K, Croner RS, Yedibela S, Hohenberger W, Schellerer VS.
    Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
    [Abstract] [Full Text] [Related]

  • 3. Detection of cytomegalovirus and human herpesvirus-6 DNA in liver biopsy specimens and their correlation with rejection after liver transplantation.
    Guardia-Silva AC, Stucchi RS, Sampaio AM, Milan A, Costa SC, Boin IF.
    Transplant Proc; 2012 Oct; 44(8):2441-4. PubMed ID: 23026615
    [Abstract] [Full Text] [Related]

  • 4. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P, Weppler D, Morris MI, Russo C, Nishida S, Levi DM, Moon J, Tekin A, Selvaggi G, Island E, Arosemena L, Ruiz P, Tzakis AG.
    Transplantation; 2011 Nov 15; 92(9):1051-7. PubMed ID: 21876474
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
    Davoudi S, Kasraianfard A, Ahmadinejad Z, Najafi A, Salimi J, Makarem J, Sohrabpour AA, Jafarian A.
    Exp Clin Transplant; 2014 Mar 15; 12 Suppl 1():72-5. PubMed ID: 24635797
    [Abstract] [Full Text] [Related]

  • 6. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
    Costa C, Astegiano S, Terlizzi ME, Sidoti F, Curtoni A, Solidoro P, Baldi S, Bergallo M, Cavallo R.
    Transplant Proc; 2011 May 15; 43(4):1159-61. PubMed ID: 21620077
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
    Perrella A, Esposito C, Ioia G, Campanella L, Taglialatela D, Cuomo O.
    Transplant Proc; 2010 May 15; 42(4):1226-8. PubMed ID: 20534267
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N, Mengelle C, Esposito L, Guitard J, Mehrenberger M, Lavayssière L, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L.
    J Med Virol; 2008 Jun 15; 80(6):1012-7. PubMed ID: 18428146
    [Abstract] [Full Text] [Related]

  • 9. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 10. Influence of cytomegalovirus disease in outcome of solid organ transplant patients.
    Linares L, Sanclemente G, Cervera C, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Marcos MA, Antón A, Pumarola T, Moreno A.
    Transplant Proc; 2011 Jun 15; 43(6):2145-8. PubMed ID: 21839217
    [Abstract] [Full Text] [Related]

  • 11. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J, Thongprayoon C, Dierkhising RA, Kremers WK, Theel ES, Razonable RR.
    Liver Transpl; 2015 Apr 01; 21(4):539-46. PubMed ID: 25597303
    [Abstract] [Full Text] [Related]

  • 13. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.
    Transpl Infect Dis; 2007 Dec 01; 9(4):286-94. PubMed ID: 17511819
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 01; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

  • 15. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 16. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 17. Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation.
    Sampaio AM, Guardia AC, Milan A, Sasaki AN, Andrade PD, Bonon SH, Stucchi RS, Botelho Costa SC, Boin IF.
    Transplant Proc; 2012 Oct 02; 44(8):2455-8. PubMed ID: 23026619
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R.
    Clin Transplant; 1997 Oct 02; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 02; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK, Saigal S, Choudhary NS, Saha S, Sah JK, Saraf N, Kumar N, Goja S, Rastogi A, Bhangui P, Soin AS.
    Transpl Infect Dis; 2018 Aug 02; 20(4):e12905. PubMed ID: 29668120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.